Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Phase 1/2 Completed
158 enrolled
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
Phase 2 Completed
23 enrolled 12 charts
Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Phase 2 Completed
56 enrolled
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
Phase 3 Terminated
270 enrolled 8 charts
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
Phase 3 Completed
503 enrolled 12 charts
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Phase 1/2 Completed
69 enrolled 27 charts
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
Phase 2 Completed
148 enrolled 7 charts
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Phase 3 Unknown
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Phase 3 Unknown
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
Phase 1/2 Unknown
16 enrolled
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Unknown
26 enrolled
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
Phase 3 Unknown
242 enrolled
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
92 enrolled
ZD 1839 in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
Phase 2 Completed
Gefitinib in Treating Patients With Cervical Cancer
Phase 2 Completed
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 2 Completed
144 enrolled
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Phase 2 Completed
50 enrolled
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Phase 2 Completed
90 enrolled
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Phase 2 Completed
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Phase 1 Completed
22 enrolled
Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
90 enrolled
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Phase 3 Completed
840 enrolled
Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
Phase 2 Completed
59 enrolled
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2 Completed
60 enrolled
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase 1 Terminated
30 enrolled
Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
41 enrolled
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
132 enrolled
Gefitinib in Treating Children With Refractory Solid Tumors
Phase 1 Completed
45 enrolled
Gefitinib in Treating Patients With Malignant Mesothelioma
Phase 2 Completed
40 enrolled
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
Phase 2 Terminated
50 enrolled
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
Phase NA Completed
40 enrolled
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase 1 Completed
30 enrolled
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Phase 2 Unknown
35 enrolled